Outcomes of ICU patients treated with intravenous immunoglobulin for sepsis or autoimmune diseases

Milena Tocut, Tamara Kolitz, Ora Shovman, Yael Haviv, Mona Boaz, Shira Laviel, Stav Debi, Mona Nama, Amir Akria, Yehuda Shoenfeld, Arie Soroksky, Gisele Zandman-Goddard*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Objectives: To evaluate the outcomes of hospitalized patients in two intensive care units (ICU) treated with intravenous immunoglobulin (IVIg) added to standard-of-care therapy. The indications for IVIg therapy were sepsis or autoimmune disease. Methods: We conducted a retrospective study involving adult patients with sepsis and autoimmune diseases, who received IVIg in the ICU at Wolfson and Sheba Medical Centers. A predefined chart was compiled on Excel to include a complete demographic collection, patient comorbidities, chronic medication use, disease severity scores (Charlson Comorbidity Index; SOFA and APACHE II index scores), indication and dosage of IVIg administration, duration of hospitalization and mortality rates. Results: Patients (n - 111) were divided into 2 groups: patients with sepsis only (n-67) and patients with autoimmune disease only (n-44). Septic patients had a shorter ICU stay, received IVIg early, and had reduced mortality if treated with high dose IVIg. Patients with autoimmune diseases did not have a favorable outcome despite IVIg treatment. In this group, IVIg was administered later than in the sepsis group. Conclusions: IVIg therapy improved the outcomes for ICU patients with sepsis.

Original languageEnglish
Article number103205
JournalAutoimmunity Reviews
Issue number12
StatePublished - Dec 2022


  • Autoimmune diseases
  • IVIg
  • Intensive care unit
  • Intravenous immunoglobulins
  • Sepsis
  • Septic shock


Dive into the research topics of 'Outcomes of ICU patients treated with intravenous immunoglobulin for sepsis or autoimmune diseases'. Together they form a unique fingerprint.

Cite this